Pipeline Insight: Antidyslipidemics

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-08-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor estimates that there are 267m people in the seven major markets with total cholesterol >200mg/dL and this is set to rise to 286m in 2015. The market has been dominated by statins for a number of years now, however, with updated guidelines taking a more aggressive approach to treatment, there is a need for more efficacious and safe alternatives on the market.


Scope

  • Patient potential for developmental antidyslipidemics over the period 2005-2015
  • Insight into the R&D pipeline with detailed information on drugs in development, clinical trial results and identification of suitable comparators
  • Evaluation of key players in the antidyslipidemics market and opposing company approaches to development and commercialization
  • Analysis of key antidyslipidemic drugs in development and their ability to satisfy major unmet needs and compete with existing agents


    • Report Highlights
    The NCEP committee updated the guidelines in 2004, taking a more aggressive approach to the treatment of dyslipidemia to help further reduce cardiovascular risk. This in turn has increased the need for alternative drugs that can help lower LDL cholesterol to meet the new lower threshold without putting patients at risk.

    The antidyslipidemic R&D pipeline is still relatively young with 91% of drugs in Phase I and II. There also appears to be a lot of investment in adjunctive therapies with approximately 69% of the drugs in the pipeline representing this class.

    Datamonitor has identified Pfizer's atorvastatin + torcetrapib combination drug and Japan Tobacco's JTT-705 as the most promising drugs in the pipeline. The atorvastatin + torcetrapib combination target both LDL and HDL with a synergistic effect which means it may offer significant advantages in efficacy with improved safety.


    Reasons to Purchase

  • View independent sales forecasts for drugs in late stage development for treatment of dyslipidemia
  • Examine the classes of products in development by phase and the challenges they have to face to reach the market
  • Identify early-stage antidyslipidemic compounds with high potential being developed by companies seeking a marketing partner

    • Table of Contents

    Other users found this report page using the following search terms: Dyslipidemia Antidyslipidemia Antidyslipidemic AntiDyslipidemia Antidyslipidemia Antidyslipidemic Antidyslipidemic obesity cholesterol dyslipidemia pipeline epidemiology swot atorvastatin analysis sales metformin antidyslipidemics 2007

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.